AACC uses Cookies to ensure the best website experience. Continuing without changing Cookie settings assumes you consent to our use of cookies on this device. You can change these settings at any time, but that may impair functionality on our websites. Review our cookie and privacy policy

Disclosures

From the May 1, 2019 Article: Tools for Combatting a Silent Epidemic

The following disclosures belong to interviewees in the CLN article, "Tools for Combatting a Silent Epidemic," published in the May 2019 issue.

Loomba is a consultant for Siemens.

Neuschwander-Tetri has consulting and/or advising relationships with Allergan, Arrowhead, Blade, Boehringer Ingleheim, BMS, Coherus, Consynance, Durect, Enanta, Gelesis, Gilead, Intercept, Lipocine, Madrigal, Medimmune, Merck, Metacrine, NGM, pH-Pharma, Prometheus, Siemens

Rinella has consulting, educating, and/or advising relationship with Enanta Pharmaceuticals, Inc., Fishawack Communications, Focus Medical Communications, LLC, Gilead Sciences, Inc., Huron Consulting Group, Inc., Indiana University, Integritas Communications, Intercept Pharmaceuticals, Inc., KL Logistics, NGM Biopharmaceuticals, Inc., Novartis, NuSirt Biopharma, Pfizer, Inc., SC Liver Research Consortium, LLC, Symbiotix.

 

Scott L. Friedman, M.D. – Disclosures, February 2019

Company Clinical Area Approved Drug/Device

Abide Therapeutics

NASH therapeutics

None

Allergan Pharmaceuticals

NASH therapeutics

None

Angion Biomedica

Fibrosis therapeutics

None

Blade Therapeutics

Fibrosis therapeutics

None

Can-Fite Biopharma

Liver cancer therapeutics

None

Enanta Pharmaceuticals

NASH therapeutics

None

Escient Therapeutics

Liver Therapeutics

None

Forbion

NASH therapeutics

None

Galmed

NASH therapeutics

None

Genfit

NASH therapeutics

None

Glycotest

Liver cancer diagnostics

None

Glympse Bio

Liver fibrosis diagnostics

None

Metacrine Inc.

NASH therapeutics

None

Mistral Biosciences

NASH therapeutics

None

Morphic Rock Therapeutics

Fibrosis therapeutics

None

North Sea Therapeutics

NASH therapeutics

None

Novartis

NASH therapeutics

None

Novo Nordisk

NASH therapeutics

None

Pfizer Pharmaceuticals

Fibrosis therapeutics

None

Salix Pharmaceuticals

NASH therapeutics

None

Scholar Rock

Fibrosis therapeutics

None

Seal Rock Therapeutics

NASH therapeutics

None

Second Genome

NASH therapeutics

None

Surrozen

Liver therapeutics

None

Symic Bio

NASH therapeutics

None

Viking Therapeutics

Fibrosis therapeutics

None

Kintai

NASH therapeutics

None

Stock Options (all less than 1% of company value):

  • Akarna Therapeutics
  • BirdRock Bio
  • Blade Therapeutics
  • Conatus
  • DeuteRx
  • Exalenz
  • Galectin
  • Galmed
  • Genfit
  • Glympse
  • Intercept
  • Jecure Therapeutics
  • Lifemax
  • Nimbus
  • Northern Biologics
  • Scholar Rock
  • Tobira Therapeutics

Research Contracts (Cell culture or animal studies)

  • Blade Therapeutics
  • Can-Fite Biopharma
  • Ferring Research Institute.
  • Galmed

Stock Ownership

  • Intercept
  • Exalenz
  • Madrigal